BioNTech SE
22UA
Rankning i aktier
#993
BioNTech SE is a biotechnology firm dedicated to the research, development, and... BioNTech SE is a biotechnology firm dedicated to the research, development, and marketing of immunotherapies for oncology and a spectrum of infectious diseases. Its diverse product pipeline features several FixVac candidates, including BNT111, currently undergoing Phase II clinical trials for advanced melanoma; BNT112, in Phase I/IIa development for prostate cancer; BNT113, progressing through Phase II for HPV-positive head and neck cancers; BNT114, in Phase I for triple-negative breast cancer; BNT115, also in Phase I for ovarian cancer; and BNT116, a preclinical asset targeting non-small cell lung cancer. Further expanding its oncology focus, BioNTech is advancing neoantigen-specific immunotherapies like Autogene cevumeran (BNT122), which is in Phase II trials for first-line melanoma and Phase 1a/1b trials for multiple solid tumors. The company's mRNA intratumoral immunotherapy, SAR441000, is undergoing Phase I evaluation for solid tumors, complemented by additional neoantigen-specific programs BNT141 and BNT142, both in Phase I clinical studies for various solid malignancies. The firm's portfolio also encompasses RiboCytokines, such as BNT151, BNT152, and BNT153, designed to treat solid tumors. Chimeric antigen receptor T cell (CAR T) immunotherapies include BNT211, aimed at multiple solid tumors, and BNT221 for other cancer types. Additionally, checkpoint immunomodulators GEN1046 and GEN1042 are in Phase I/II clinical development for solid tumor indications. Beyond these, BioNTech is developing BNT321, an IgG1 monoclonal antibody in Phase II trials for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. The company is also actively involved in the creation of prophylactic vaccines for COVID-19 and Influenza, alongside other infectious disease immunotherapies and therapies for rare diseases involving protein replacement. BioNTech maintains strategic alliances with several prominent pharmaceutical and biotechnology entities, including Genentech, Inc., Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE's corporate headquarters are located in Mainz, Germany.
Aktiekurs
$94.89
Senast synkroniserad: 2026-10-20
Marknadsvärde
$23.84B
Förändring (1 dag)
1.65%
Förändring (1 år)
-11.37%
Land
DE
Handel BioNTech SE (22UA)
Kategori
Healthcare
P/E-tal för BioNTech SE (22UA)
P/E-tal per October 2026 TTM: -11.72
Enligt BioNTech SE senaste finansiella rapporter och aktiekurs är det aktuella P/E-talet (TTM) -11.72. I slutet av 2023 hade företaget ett P/E-tal på 24.57.
Historik för P/E-tal för BioNTech SE från 2016 till 2026
P/E-tal vid slutet av varje år
| År | P/E-tal | Ändra |
|---|---|---|
| 2026 (TTM) | -11.72 | -70.17% |
| 2024 | -39.28 | -259.83% |
| 2023 | 24.57 | 566.38% |
| 2022 | 3.69 | -27.41% |
| 2021 | 5.08 | -99.55% |
| 2020 | 1.13K | -3,248.09% |
| 2019 | -35.91 | -41.40% |
| 2018 | -61.28 | 78.37% |
| 2017 | -34.35 | 0.00% |
| 2016 | 0.00 | 0.00% |
P/E-tal för liknande företag eller konkurrenter
| Företag | P/E-tal | Skillnad i P/E-tal | Land |
|---|---|---|---|
| 28.78 | -345.61% |
US
|
|
| -28.36 | 142.00% |
US
|
|
| -24.57 | 109.64% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -358.82% |
NL
|
Hur man läser ett P/E-tal
P/E-talet (Price/Earnings) mäter förhållandet mellan ett företags aktiekurs och dess vinst per aktie.
Ett lågt men positivt P/E visar ett företag med hög vinst i förhållande till värderingen och kan vara undervärderat. Ett högt negativt (nära 0) P/E indikerar stora förluster.
Företag med P/E över 30 eller negativt ses ofta som "tillväxtaktier", vilket innebär att investerare förväntar sig tillväxt eller framtida lönsamhet.
Företag med positivt P/E under 10 ses som "värdeaktier" och är redan lönsamma men med begränsad tillväxtpotential.